Benlysta Approved for Lupus
Benlysta (belimumab) has been approved by the U.S. Food and Drug Administration to treat lupus, the first medication sanctioned for the condition in the United States since 1955.
THURSDAY, March 10 (HealthDay News) -- Benlysta (belimumab) has been approved by the U.S. Food and Drug Administration to treat lupus, the first medication sanctioned for the condition in the United States since 1955.
The injected drug targets B-lymphocyte stimulator (BLyS) protein, which is believed to play a role in abnormal B cells thought to characterize lupus, the agency said in a news release. Lupus disproportionally affects women, usually aged 15 to 44.
As many as 1.5 million people in the United States have the disease, although estimates vary widely, the FDA said. Black women have a three times higher incidence of the disease than Caucasian women.
The safety and effectiveness of Benlysta were established in a pair of clinical studies involving 1,684 people. Those treated with Benlysta had fewer symptoms than those who took a placebo, and the results suggested that those who took the drug also were less likely to have severe lupus flares, the agency said.
Common side effects of the drug included nausea, diarrhea and fever.
Blacks and people of African heritage didn't respond to the new drug, and the FDA said it ordered Benlysta's manufacturer to conduct additional studies involving these patients.
Benlysta was developed by Human Genome Sciences, based in Rockville, Md., and will be co-marketed by Philadelphia-based GlaxoSmithKline.
More information
To learn more about lupus, visit the Lupus Foundation of America.
Severe maternal morbidity linked to mental health risks post-delivery
April 26th 2024A recent study revealed that severe maternal morbidity during pregnancy increases the likelihood of mental health hospitalizations or emergency department visits up to 13 years post-delivery, emphasizing the need for mental health screening.
Read More
FDA approves updated label for Biktarvy against HIV-1
April 26th 2024Gilead Sciences has announced FDA approval of an updated Biktarvy label, showcasing safety and efficacy data from a phase 1b trial, positioning it as a pivotal treatment option for pregnant individuals with HIV-1 and suppressed viral load.
Read More
No link found between antenatal corticosteroids and child neurodevelopment
April 25th 2024A recent study found no link between antenatal corticosteroid administration and adverse neurodevelopmental outcomes in children aged 6 years or older, offering reassurance for late preterm delivery practices.
Read More
